Gallium Ga 68 FAPi-46 for Cholangiocarcinoma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Cholangiocarcinoma+25 More
Gallium Ga 68 FAPi-46 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is looking at a new way to image cancer using a tracer called 68Ga-FAPi-46. The tracer is taken up by some cancers, and can be seen with PET imaging. This may provide additional information about various cancers in the future.

Eligible Conditions
  • Cholangiocarcinoma
  • Neuroendocrine Neoplasms
  • Testicular Neoplasms
  • Liver carcinoma
  • Neoplasms
  • Carcinoma
  • Malignant Solid Neoplasms
  • Cervical Carcinoma
  • Malignant Neoplasms of Brain
  • Malignant Pleural Neoplasm
  • Lymphoid Cells
  • Malignant Adrenal Gland Neoplasm
  • Malignant Thymus Neoplasm
  • Transitional Cell, Carcinoma
  • Urinary Bladder

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Up to year 2

60 minutes after tracer injection
Positron-Emission Tomography
At 20-90 minutes after injection]
Biodistribution of gallium 68Ga-FAPi-46 in normal and cancer tissues
Up to year 2
68Ga-FAPi-46 accumulation observed by positron emission tomography (PET)/computed tomography (CT)

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Basic science (68GA-FAPI-46 PET/CT)
1 of 1
Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: Gallium Ga 68 FAPi-46 · No Placebo Group · Phase 1

Basic science (68GA-FAPI-46 PET/CT)Experimental Group · 3 Interventions: Gallium Ga 68 FAPi-46, Positron Emission Tomography, Computed Tomography · Intervention Types: Drug, Procedure, Procedure
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Positron Emission Tomography
2008
Completed Phase 2
~2820
Computed Tomography
2017
Completed Phase 2
~3410

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to year 2

Who is running the clinical trial?

Jonsson Comprehensive Cancer CenterLead Sponsor
338 Previous Clinical Trials
21,639 Total Patients Enrolled
1 Trials studying Cholangiocarcinoma
Jeremie CalaisPrincipal InvestigatorUCLA / Jonsson Comprehensive Cancer Center
6 Previous Clinical Trials
1,251 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have testicular cancer.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 31st, 2021

Last Reviewed: October 16th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.